Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Novo Nordisk

18-Dec-2003

Genaissance Pharmaceuticals, Inc. announced that it has licensed its HAP(TM) Technology to Novo Nordisk A/S for use in a drug development program. Under the terms of the agreement, Novo Nordisk will pay Genaissance license and service fees, including fees for genotyping clinical samples. Genaissance will have certain rights to develop and commercialize specified diagnostic products and services.

"We are pleased that Novo Nordisk chose our HAP(TM) Technology to address their pharmacogenomic need," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Novo Nordisk has been utilizing our Good Laboratory Practices DNA and genotyping services and this agreement expands the scope of our work with them, demonstrating how our various pharmacogenomic capabilities can benefit our customer base."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance